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Abstract
Introduction: Saw palmetto is a phytotherapeutic agent commercially marketed for the treatment of benign
prostatic hyperplasia. Evidence suggests that saw palmetto is a safe product, and mild gastrointestinal adverse
effects have been reported with its use. We report a case of acute pancreatitis, possibly secondary to the use of
saw palmetto.
Case presentation: A 61-year-old Caucasian man with a history of benign prostatic hyperplasia and
gastroesophageal reflux disease developed epigastric pain associated with nausea 36 hours prior to presentation.
He denied drinking alcohol prior to the development of his symptoms. His home medications included saw
palmetto, lansoprazole and multivitamins. Laboratory results revealed elevated lipase and amylase levels. An
abdominal ultrasound demonstrated a nondilated common bile duct, without choledocholithiasis. Computed
tomography of his abdomen showed the pancreatic tail with peripancreatic inflammatory changes, consistent with
acute pancreatitis. Our patient’s condition improved with intravenous fluids and pain management. On the fourth
day of hospitalization his pancreatic enzymes were within normal limits: he was discharged home and advised to
avoid taking saw palmetto.
Conclusion: It is our opinion that a relationship between saw palmetto and the onset of acute pancreatitis is
plausible, and prescribers and users of saw palmetto should be alert to the possibility of such adverse reactions.
Introduction
Serenoa repens (W. Bartram) Small, more commonly
known as saw palmetto or scrub palmetto, is a low-
growing palm endemic to the Southeastern United
States [1]. Ecologically, saw palmetto is used for nesting,
protective cover and as a food source by wildlife. The
medicinal value of the fruit among humans has been
described in scientific literature since the 1800s for the
relief of prostate gland swelling [2].
The liposterolic extract of saw palmetto has antian-
drogenic activity in human prostatic cell lines [3].
Furthermore, it inhibits binding of dihydrotestosterone
(DHT) to its receptor [4] and prevents the conversion of
testosterone into DHT by inhibiting the activity of 5-
alpha-reductase [5], exhibiting a similar mechanism to
the Food and Drug Administration (FDA) -approved
medication finasteride. In vitro studies have shown that
it also inhibits cyclooxygenase and 5-lipoxygenase path-
ways, thereby preventing the biosynthesis of inflamma-
tion-producing prostaglandins and leukotrienes [6].
As a phytotherapeutic agent, saw palmetto is currently
being commercially marketed for the treatment of
benign prostatic hyperplasia (BPH). A systematic review
of randomized control trials of saw palmetto, involving
2939 men, reported similar improvement in the urologic
symptoms of BPH and urinary flow measures compared
with finasteride. Furthermore, it was associated with
fewer adverse effects [7]. However, a more recent dou-
ble-blind randomized control trial of 225 men, compar-
ing a saw palmetto and a placebo group, showed no
significant difference in their American Urological Asso-
ciation Symptom Index scores or maximal urinary flow
rate, with the incidence of side effects similar between
the two groups [8]. The latest Cochrane review with
5222 subjects from 30 randomized trials also confirmed
that saw palmetto was well tolerated, but was no better
than placebo in improving urinary symptoms, peak
urine flow, or prostate size for men with BPH [9].
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BPH, current evidence suggest that saw palmetto is
well-tolerated by patients and is not associated with ser-
ious adverse events. Concomitantly, most adverse events
reported were mild, infrequent and reversible. A sys-
tematic review of adverse events by Agbabiaka et al.
from monopreparations of saw palmetto suggests that
adverse events associated with its use are similar to
those occurring in placebo groups. Adverse effects that
have been frequently reported include abdominal pain,
diarrhea, nausea and fatigue, headache, decreased libido
and rhinitis [10].
More serious adverse effects have also been reported
in isolated case reports, including protracted cholestatic
hepatitis after the use of Prostata, an herbal preparation
used for prostatic hypertrophy with saw palmetto as
presumably the most active ingredient [11], and acute
pancreatitis. To date there have been two case reports
of acute pancreatitis associated with saw palmetto use
[12,13]. Acute pancreatitis accounts for more than
200,000 hospital admissions annually in the United
States and its hospitalization rate is rising [14]. It ranks
third in the list of hospital discharges for gastrointestinal
related diseases. Mortality from acute pancreatitis is less
than 5% overall, but severe cases cause prolonged hospi-
talization and significantly higher mortality [15]. We
report a case of acute pancreatitis, possibly secondary to
the use of saw palmetto, and review the other cases in
the literature of this condition.
Case presentation
A 61-year-old Caucasian man with a history of BPH and
gastroesophageal reflux disease, who has been in his
usual state of health until 36 hours prior to presenta-
tion, developed epigastric pain characterized as dull,
constant, non-radiating, aggravated by positional
changes without any alleviating factors and associated
with nausea. He denied any similar episode of abdom-
inal pain in the past. On physical examination, our
patient was febrile at 38.5°C and tachycardic; his abdo-
men was soft with epigastric and periumbilical tender-
ness and minimal guarding. He occasionally drank a
bottle of beer every two to three weeks but denied
drinking alcohol recently, had a remote smoking history,
and denied any illicit drug use. His home medications
included saw palmetto, which he had been taking for
the past three years, lansoprazole and multivitamins. His
BPH was initially treated with tamsulosin by his urolo-
gist, however he experienced dizziness with this medica-
tion and was unable to tolerate it. He was then
prescribed saw palmetto, which offered relief for his
BPH symptoms.
Laboratory results upon admission revealed elevated
lipase and amylase levels at 4406 units/L (reference
range, RR 20-104 units/L) and > 3500 units/L (RR 5.6-
51.3 units/L), respectively. Triglycerides were normal at
145 mg/dL (RR < 250 mg/dL); his alcohol level was less
than 10 mg/dL (RR 0-80 mg/dL).
Our patient’s liver function tests were normal: aspar-
tate transaminase 35 units/L (RR 8-20 units/L), alanine
transaminase 33 units/L (RR 10-40 units/L), alkaline
phosphatase 140 units/L (RR 27-100 units/L) and total
bilirubin 0.6 mg/dL (RR < 20 mg/dL). Basic metabolic
panels were also within normal limits. His calcium level
was 9.3 mg/dL (RR 8.5 10.4 mg/dL).
A complete blood count was unremarkable except for
leukocytosis at 14.1 × 10
3cells/mm
3. An abdominal
ultrasound demonstrated a common bile duct, measur-
ing 0.5 cm in diameter, without cholelithiasis (Figure 1).
Computed tomography (CT) of his abdomen with con-
trast showed that his pancreatic tail was indistinct with
peripancreatic inflammatory changes, consistent with
acute pancreatitis (Figure 2). Our patient was diagnosed
with acute pancreatitis and treated with supportive care,
which included intravenous fluids and pain manage-
ment. Our patient’s pain improved, his diet was slowly
advanced, and home medications were resumed with
the exception of saw palmetto. On the fourth day of
hospitalization, his pancreatic enzymes were within nor-
mal limits; he was discharged home with a lipase of 32
units/L and advised to avoid taking saw palmetto.
Discussion
The most common causes for pancreatitis in adults are
cholelithiasis and excessive alcohol use, accounting for
35-40% and 30% of cases, respectively. Other causes
include anatomic variants of the pancreas, mechanical
obstruction to pancreatic juice, hypertriglyceridemia,
Figure 1 Abdominal ultrasonography showed no evidence for
gallstones; common bile duct was not dilated and measured
0.5 cm.
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infections and autoimmune conditions [16]. Many medi-
cations also have been identified as a probable cause of
a c u t ep a n c r e a t i t i s .T h ef i r s tt or e p o r tac a s eo fd r u g -
induced acute pancreatitis was Zion et al. in 1955; they
described a case of hemorrhagic pancreatitis associated
with cortisone therapy [17]. Drug-induced pancreatitis
is rare, although more than 100 drugs have been impli-
cated in causing this condition. It is rarely accompanied
by clinical or laboratory evidence of a drug reaction,
such as eosinophilia and rash [18]. Definite association
of drugs with acute pancreatitis include aminosalicy-
lates, L-asparaginase, azathioprine, didanosine, estrogen,
furosemide, pentamidine, sulfonamide, tetracycline, thia-
zides, valproic acid, vinca alkaloids and 6-mercaptopur-
ine [16].
A detailed history and physical examination along
with routine radiological evaluation consisting of ultra-
sound and/or CT of the abdomen can detect the under-
lying etiology of acute pancreatitis in approximately 80%
of patients. If this initial investigation is unrevealing, the
patient is classified as having idiopathic acute pancreati-
tis [19].
In our patient, cholelithiasis, hypertriglyceridemia,
infection and trauma were ruled out as possible causes
of pancreatitis. In addition, as per the history of our
patient, he had no recent alcohol use and consumption
was very minimal.
Though confirmation of microlithiasis and anatomic
variants of the pancreas such as papillary stenosis and
sphincter of Oddi dysfunction are most accurately
obtained using endoscopic ultrasonography, magnetic
resonance cholangiopancreatography or sphincter of
Oddi manometry [20], these procedures were not pur-
sued in our patient because of his clinical presentation
and subsequent improvement.
The required extensiveness of a search for the etiology
in a patient with a first episode of unexplained pancrea-
titis is still a matter of debate [21]. A retrospective study
which looked at patients presenting with a first episode
of unexplained acute pancreatitis showed that only
about 3.2% (one in 31 cases) would suffer another attack
during a median follow-up of 36 months [22], suggest-
ing that extensive investigation for unusual causes of
pancreatitis may not required after the first episode of
unexplained pancreatitis. Furthermore, invasive testing
is associated with procedure-related complications and
the relationship between some of those findings and the
etiology of the pancreatitis is not always clear [23].
Based on local expertise, advanced evaluation is defi-
nitely indicated in patients with a severe initial attack of
acute pancreatitis or with two or more attacks [19].
An association between acid suppressing drugs and
acute pancreatitis has not been clearly supported by
cohort and case control studies. Although proton pump
inhibitors like omeprazole, pantoprazole and rabeprazole
have been implicated in drug-induced pancreatitis, no
case report for other proton pump inhibitors like lanso-
prazole has been described [24,25].
Apart from our patient and two other case reports, no
other data on saw palmetto-induced acute pancreatitis
have been reported. Our case and previous case reports
(Table 1) reveal consistent resolution of symptoms and
pancreatic enzymes following discontinuation during
brief hospitalization (three to four days) which is consis-
tent with the short half-life of saw palmetto [26]. To the
best of our knowledge, this is the first reported case of
acute pancreatitis with a normal alanine transaminase
level, which goes against the probability of gallstone
pancreatitis [27].
Figure 2 Abdominal CT scan with contrast showed an
indistinct pancreatic tail with peripancreatic inflammatory
changes consistent with pancreatitis.
Table 1 Characteristics of three patients with saw palmetto-induced pancreatitis
Case Number
[Ref#]
Age
(years)
Sex Amylase
(Units/L)
Lipase
(Units/L)
AST
(Units/L)
ALT
(Units/L)
Days of resolution
1 [12] 55 M 2152 39,346 1265 1232 four
2 [13] 65 M 626 2697 n/a n/a three
3 [our case] 61 M 4406 > 3500 35 33 four
ALT: alanine transminase; AST: aspartate transminase
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drug-induced acute pancreatitis from 1955 to 2006, they
classified reported medications into four classes based
on the published weight of evidence for each agent and
the pattern of clinical presentation. Class I included
medications in which at least one case was proven by a
re-challenge with the drug. Class II included drugs with
a consistent latency in 75% or more of the reported
cases. Class III included drugs that had two or more
case reports published, but neither a re-challenge nor a
consistent latency period. Class IV drugs were similar to
class III drugs, but only one case report had been found
[18]. Based on the aforementioned classification, saw
palmetto could be placed as a Class III agent for drug-
induced acute pancreatitis.
The mechanisms of action for drug-induced acute
pancreatitis are based on theories extracted from case
reports, case-control studies, animal studies and other
experimental data. In general, some potential mechan-
isms of action for drug-induced acute pancreatitis
include pancreatic duct constriction, cytotoxic and
metabolic effects, accumulation of a toxic metabolite or
intermediary and hypersensitivity reactions [28]. A
mechanism for saw palmetto-induced pancreatitis has
not been thoroughly established. One theory suggests
that it occurs through its estrogenic effects by stimulat-
ing estrogen receptors; it then induces a hypercoagulable
state that leads to pancreatic necrosis [29]. However, as
in the two previous case reports, pancreatic necrosis was
not observed in our patient.
It is also important to note that the United States
FDA regulate dietary supplements under a different set
of regulations than those covering “conventional” foods
and drug products, where the dietary supplement man-
ufacturer is responsible for ensuring that a supplement
is safe before it is marketed. FDA is responsible for
taking action against any unsafe supplement product
after it reaches the market; hence the lack of a stan-
dard premarketing regulation for dietary supplements
[30].
Conclusion
Current data show that the risk of drug-induced acute
pancreatitis is low and it is imperative to rule out more
common causes before attributing the event to a certain
medication. Three case reports of probable saw pal-
metto-induced pancreatitis have been described and all
the patients had been taking the medication for BPH
symptoms. Even with a relatively safe profile as shown
by studies on patients taking saw palmetto, the risk of
having an adverse reaction exists and warrants immedi-
ate withdrawal of the drug and further investigation to
prevent serious consequences.
Except for the fact that our patient took saw palmetto,
there was no established cause of his acute pancreatitis.
Our case highlights the importance of taking a detailed
medication history including phytotherapeutic agents in
all patients and prompt discontinuation of a probable
offending drug to ensure patient safety.
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